Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company” or “Sona”) is pleased to announce that it has closed its non-brokered private placement that was announced on July 31, 2024 with the issuance of 6,000,000 common shares (each, a “Share”) at $0.25 per share, (the “Financing”).
Antler Gold Inc. (“Antler” or the “Company”) (TSX-V:ANTL) is pleased to announce that its subsidiary, Antler Gold Namibia (Pty) Ltd (“Antler Nam”), has signed a binding Letter Of Intent (“LOI”) with Fortress Asset Management LLC (“Fortress” or the “Optionee”), an arms-length private company.
Halifax, Nova Scotia – (Newsfile Corp. August 1, 2024) – E-Tech Resources Inc. (“E-Tech” or the “Company“) (TSX.V:REE) (FSE:K2i) is pleased to announce the closing of its previously announced private placement of 12,000,000 units (each, a “Unit“) at $0.05 per Unit. Each Unit consists of one common share of E-Tech (a “Common Share”) and one-half common share purchase […]
E-Tech Resources Inc. (“E-Tech” or the “Company“) (TSX.V:REE) (FSE:K2i) is pleased to announce the closing of its previously announced private placement of 12,000,000 units (each, a “Unit“) at $0.05 per Unit. Each Unit consists of one common share of E-Tech (a “Common Share”) and one-half common share purchase warrant (each whole warrant, a “Warrant“) for gross proceeds of $600,000 (the “Financing“). Each Warrant entitles the holder to acquire one Common Share of E-Tech at an exercise price of $0.10 per share for a period of 24 months from closing. The proceeds from the private placement will be used to support the Company’s ongoing exploration and operational activities as well as for general working capital purposes.
Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company”, “Sona”) is pleased to announce that it plans to raise up to $1,500,000 through a private placement financing (the “Financing”) of up to 6,000,000 common shares of Sona (each, a “Share”) at a price of $0.25 per Share (the “Offering Price”). Insiders and certain other existing shareholders of Sona may also subscribe for Shares under the Financing.
HALIFAX, NS July 24, 2024 – Fortune Bay Corp. (TSXV:FOR, FWB:5QN, OTCQB: FTBYF) (“Fortune Bay” or the “Company”) is pleased to announce completion of the 2024 summer drill program on the Murmac Uranium Project (“Murmac” or the “Project”), located in northern Saskatchewan near Uranium City. The program was designed to test regional targets across the Project […]
Halifax, Nova Scotia – (July 22, 2024) – E-Tech Resources Inc. (“E-Tech” or the “Company”) (TSX.V:REE) (FSE:K2i) is pleased to announce that it plans to raise up to $600,000 through a private placement (the “Financing”) of up to 12,000,000 units of E-Tech (each, a “Unit”) at $0.05 per Unit. Each Unit will consist of one common […]
Sona Nanotech Inc. (CSE: SONA)(OTCQB: SNANF) (the “Company” or “Sona”) is pleased to announce that its targeted hyperthermia therapy (“THT”) demonstrated positive results in a second preclinical cancer model. Findings just presented at the 2024 STING & TLR Targeted Therapies Summit for immunotherapies in San Diego, California, show that Sona’s THT achieved responses in a preclinical melanoma model equal to that which was recently reported from its triple negative breast cancer study. THT effectively treated melanoma tumors in all animals when administered on its own. Further, when THT was combined with doses of interleukin-2 (“IL-2”), a standard immunotherapy, a synergistic effect was shown whereby greater treatment response, measured by tumor volume reduction, was achieved in comparison to either approach alone.
HALIFAX, NS June 25, 2024 – Fortune Bay Corp. (TSXV:FOR, FWB:5QN, OTCQB: FTBYF) (“Fortune Bay” or the “Company”) is pleased to announce the intersection of highly elevated radioactivity in the second drill hole (M24-017) of its 2024 exploration drilling program on the Murmac Uranium Project (“Murmac” or the “Project”), located in northern Saskatchewan. An average of 1,309 […]
Sona Nanotech Inc. (CSE: SONA)(OTCQB: SNANF) (the “Company” or “Sona”) is pleased to announce that its targeted hyperthermia therapy (“THT”) demonstrated positive results in a second preclinical cancer model. Findings just presented at the 2024 STING & TLR Targeted Therapies Summit for immunotherapies in San Diego, California, show that Sona’s THT achieved responses in a preclinical melanoma model equal to that which was recently reported from its triple negative breast cancer study. THT effectively treated melanoma tumors in all animals when administered on its own. Further, when THT was combined with doses of interleukin-2 (“IL-2”), a standard immunotherapy, a synergistic effect was shown whereby greater treatment response, measured by tumor volume reduction, was achieved in comparison to either approach alone.